A Patient Undergoing Treatment of Hematologic Malignancy Reports for Oral Evaluation

Payam Mirfendereski; Katherine France

doi:10.1016/j.cden.2023.05.016

A Patient Undergoing Treatment of Hematologic Malignancy Reports for Oral Evaluation

Dent Clin North Am. 2023 Oct;67(4):663-665. doi: 10.1016/j.cden.2023.05.016. Epub 2023 Jun 18.

Authors

Payam Mirfendereski¹, Katherine France²

Affiliations

¹ Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA.
² Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA. Electronic address: kfrance@upenn.edu.

PMID: 37714619
DOI: 10.1016/j.cden.2023.05.016

Abstract

Oral lesions are commonly seen in patients with acute myeloid leukemia (AML) and may be the first clinical signs of disease. It is important for the dental provider to be able to recognize the oral manifestations of AML to allow for timely referral to a medical specialist. Patients with AML may receive treatment through chemotherapy, targeted drug therapies, or stem cell transplantation, which can involve oral complications and therefore necessitate case-specific patient education, dental evaluation, and treatment planning.

Keywords: Acute myeloid leukemia; Chemotherapy; Leukemic gingival infiltration; Opportunistic infection; Oral manifestations.

Publication types

Review

MeSH terms

Hematologic Neoplasms* / therapy
Humans
Referral and Consultation
Stem Cell Transplantation